Lymphoma

Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma

Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma

By

In this analysis, researchers measured the impact and effectiveness of supportive treatments for moderate to severe anemia in patients with lymphoma or multiple myeloma, based on patient-reported outcomes.

A Rare Case of Classical Hodgkin Lymphoma 10 Years After Liver Transplantation

A Rare Case of Classical Hodgkin Lymphoma 10 Years After Liver Transplantation

By

This case describes management of a 61-year-old male with a history of chronic liver diseases and COPD who developed a posttransplant lymphoproliferative disorder 10 years after a liver transplant.

Brentuximab Vedotin Granted FDA Approval for pcALCL, Mycosis Fungoides

Brentuximab Vedotin Granted FDA Approval for pcALCL, Mycosis Fungoides

By

The US FDA has granted regular approval to brentuximab vedotin (Adcetris) for pcALCL and CD30-expressing MF in adult patients who received prior systemic therapy.

Acalabrutinib Approved for Mantle Cell Lymphoma

Acalabrutinib Approved for Mantle Cell Lymphoma

Acalabrutinib is a treatment option for patients with mantle cell lymphoma who have not responded to prior treatment.

Critical Thinking Key to Effective Management of Adverse Effects in Lymphoma

Critical Thinking Key to Effective Management of Adverse Effects in Lymphoma

By

Nurses' critical thinking perspective is key to recognizing and managing adverse effects in patients with lymphoma, and staying ahead of the curve in a rapidly changing clinical setting.

All-Cause Mortality Improved by Advances in Radiotherapy for Hodgkin Lymphoma

All-Cause Mortality Improved by Advances in Radiotherapy for Hodgkin Lymphoma

By

Investigators assessed the impact of advances over time in the treatment of Hodgkin lymphoma on all-cause mortality in patients with Hodgkin lymphoma who received radiotherapy alone or with chemotherapy.

Palonosetron Prevents Delayed Nausea and Vomiting After CHOP in Non-Hodgkin Lymphoma

Palonosetron Prevents Delayed Nausea and Vomiting After CHOP in Non-Hodgkin Lymphoma

By

Palonosetron effectively prevents and manages delayed CINV in patients with non-Hodgkin lymphoma.

Nivolumab Improves Clinical Outcomes in Patients With Relapsed-Refractory Hodgkin Lymphoma After ASCT, Brentuximab Vedotin

Nivolumab Improves Clinical Outcomes in Patients With Relapsed-Refractory Hodgkin Lymphoma After ASCT, Brentuximab Vedotin

By

Study reports that patients with classic relapsed/refractory Hodgkin lymphoma who received nivolumab after ASCT experienced high rates of response regardless of previous history with brentuximab vedotin.

Rituximab in the Treatment of Follicular Lymphoma: the Future of Biosimilars in the Evolving Therapeutic Landscape

Rituximab in the Treatment of Follicular Lymphoma: the Future of Biosimilars in the Evolving Therapeutic Landscape

[Cancer Management and Research] This research summarizes the role of rituximab across the spectrum of FL treatment and the evolving therapeutic landscape with the emergence of novel agents currently in clinical development.

CAR T Cells: Keeping Pace With Adverse Effects of an Emerging Therapy

CAR T Cells: Keeping Pace With Adverse Effects of an Emerging Therapy

By

The oncology nurses' role in monitoring and early recognition of the signs and symptoms of CAR T-cell toxicities is significant considering the potential severity of these adverse effects.

Novel Approach Prevents GVHD After Hematopoietic Stem Cell Transplantation

Novel Approach Prevents GVHD After Hematopoietic Stem Cell Transplantation

By

An international team developed an approach to hematopoietic stem cell transplantation that prevents GVHD while preserving the benefits of the therapy.

Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors

Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors

By

Hodgkin lymphoma survivors are at higher risk of second cancers, and that risk is even higher in those with a first-degree relative with cancer.

Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL

Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL

By

Lenalidomide maintenance appears efficacious for relapsed diffuse large B cell lymphoma.

Treatment Outcomes Were Unchanged by Brentuximab Vedotin (BV)-induced Peripheral Neuropathy

Treatment Outcomes Were Unchanged by Brentuximab Vedotin (BV)-induced Peripheral Neuropathy

By

Patients who were surveyed reported that the benefits of treatment with BV outweighed its risks.

Pembrolizumab Active in Refractory NK/T-cell Lymphoma

Pembrolizumab Active in Refractory NK/T-cell Lymphoma

By

PD-1 blockade with pembrolizumab was active and induced durable responses in patients with natural killer (NK)/T-cell lymphoma failing L-asparaginase.

Hepatitis C Virus Associated With Increased Risk of Variety of Cancers

Hepatitis C Virus Associated With Increased Risk of Variety of Cancers

By

Researchers have found that hepatitis C virus infection is associated with an elevated risk for developing bile duct cancers and diffuse large B-cell lymphoma.

Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma

Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma

[OncoTargets and Therapy] This research examines the efficacy and safety of recombinant human endostatin in combination with CHOP regimen (ECHOP) for patients with peripheral T cell lymphoma.

O-DHAP and R-DHAP Equivalent As Salvage Therapy for R/R DLBCL

O-DHAP and R-DHAP Equivalent As Salvage Therapy for R/R DLBCL

By

Researchers sought to compare the efficacy of O-DHAP with R-DHAP as salvage treatment, followed by autologous hematopoietic cell transplantation.

Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma

Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma

By

The patient's history and current blood work results indicated a dangerously high potassium level. But a meticulously handled redraw proved it false.

Rituximab With High-dose Sequential Chemo Fails to Improve DLBCL Outcomes

Rituximab With High-dose Sequential Chemo Fails to Improve DLBCL Outcomes

By

Frontline treatment with rituximab plus high-dose sequential chemotherapy with autologous HSCT failed to improve progression-free or overall survival compared with R-CHOP in patients with diffuse large B-cell lymphoma.

Severe Fatigue Associated With Unemployment in Hodgkin Lymphoma Survivors

Severe Fatigue Associated With Unemployment in Hodgkin Lymphoma Survivors

By

Severe fatigue is associated with unemployment and financial problems in survivors of Hodgkin lymphoma, highlighting the need for clinicians to address fatigue in these patients.

Ciprofloxacin May Prevent Bacteremia in Patients Undergoing Auto-HSCT

Ciprofloxacin May Prevent Bacteremia in Patients Undergoing Auto-HSCT

By

Antibacterial prophylaxis with the flouroquinolone, ciprofloxacin, substantially reduced the risk of bacteremia and neutropenic fever in patients with multiple myeloma or lymphoma undergoing high-dose chemotherapy and auto-HSCT.

Carmustine Infusion Reactions Occur Despite Extending Infusion Duration

Carmustine Infusion Reactions Occur Despite Extending Infusion Duration

By

Infusion reactions during administration of high-dose carmustine as part of the BEAM conditioning regimen are common and do not appear to be reduced by modestly extending the duration of infusion or giving premedications.

Cancer-related Fatigue Common in Hodgkin Lymphoma Survivors

Cancer-related Fatigue Common in Hodgkin Lymphoma Survivors

By

There is a high incidence of severe acute and persistent cancer-related fatigue in survivors of Hodgkin lymphoma, regardless of tumor stage or treatment.

Monoclonal Antibody Shows Promise in Aggressive R/R Adult T-cell Leukemia/Lymphoma

Monoclonal Antibody Shows Promise in Aggressive R/R Adult T-cell Leukemia/Lymphoma

By

Mogamulizumab induced an encouraging response rate in patients with relapsed/refractory adult T-cell leukemia/lymphoma.

PET-CT Can Inform Decision to Omit Bleomycin in Hodgkin Lymphoma Treatment to Reduce Toxicity

PET-CT Can Inform Decision to Omit Bleomycin in Hodgkin Lymphoma Treatment to Reduce Toxicity

By

Omitting bleomycin from the treatment regimen for Hodgkin lymphoma in patients with negative findings on an interim PET scan led to a lower incidence of pulmonary toxic effects without significantly lowering treatment efficacy.

Study Confirms Lenalidomide Effective for Diffuse Large B-Cell Lymphoma

Study Confirms Lenalidomide Effective for Diffuse Large B-Cell Lymphoma

By

Lenalidomide is an effective treatment option with limited and reversible toxicities for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), a 'real-world' study has shown.

Autologous Stem Cell Transplant Safe as Standard of Care in Patients With HIV-Associated Lymphoma

Autologous Stem Cell Transplant Safe as Standard of Care in Patients With HIV-Associated Lymphoma

By

Recent results from a multicenter, phase 2 trial suggest that patients with HIV and aggressive lymphoma should receive autologous stem cell transplant as standard of care. Risk of serious complications after transplant in these patients is equal to that of patients without HIV.

aHSCT Should Be Standard of Care for HIV-Related Lymphoma

aHSCT Should Be Standard of Care for HIV-Related Lymphoma

Patients living with HIV are at high risk for lymphoma,according to recent study data, and recent autologous hematopoietic stem-cell transplantation may be preferable for these patients.

Alemtuzumab + CHOP for Peripheral T Cell Lymphoma: Higher Remission, But Not Survival

Alemtuzumab + CHOP for Peripheral T Cell Lymphoma: Higher Remission, But Not Survival

By

When added to the CHOP regimen, alemtuzumab increases remission rates in elderly patients with peripheral T cell lymphoma, final analysis of the international ACT-2 phase 3 trial presented at the ASCO 2016 Annual Meeting has shown.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs